Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.35 |
| ▸ | TACR1 | P25103 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | UGCG | Q16739 | 3/20 | 0.31 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10136315 | 0.93 | MDM2 (0.32) | DHODHTACR1MEN1KMT2ACYP3A4 | |
| SCHEMBL10136639 | 0.93 | SLC2A1 (0.34) | DHODHTACR1CETP | |
| SCHEMBL10136930 | 0.90 | CRHR1 (0.40) | — | |
| SCHEMBL10136233 | 0.89 | TACR1 (0.33) | DHODHTACR1CYP3A4UGCGCAPN1 | |
| SCHEMBL10136610 | 0.88 | DHODH (0.33) | DHODHTACR1KMT2ACYP3A4UGCG | |
| SCHEMBL10136641 | 0.88 | ALDH1A1 (0.34) | DHODHTACR1CYP3A4UGCGCAPN1 | |
| SCHEMBL10136299 | 0.86 | SLC2A1 (0.33) | DHODHCYP3A4UGCG | |
| SCHEMBL10118322 | 0.85 | ALDH1A1 (0.35) | DHODHALDH1A1 | |
| SCHEMBL10136217 | 0.84 | GRM4 (0.36) | DHODHMEN1KMT2ACAPN1ALDH1A1 | |
| SCHEMBL10136642 | 0.84 | ALDH1A1 (0.35) | DHODHCYP3A4UGCGCAPN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582688-B1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8791139-B2 | Anthranilic diamide derivatives | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | DDT, QDPR, ANTXR2 | DHODH 197/4885TACR1 591/4885MEN1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.